David Haen

2020 already looks promising for this profitable specialty pharma company despite global markets melting down.

Headwinds from COVID-19 may negatively impact 2020 projections.

In the battle between these pharma heavyweights, which one’s prospects shine brightest?

Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.

Key developments by the U.S. government could have a profound impact on the country's health insurers.

On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts tons of institutional investor support.

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

It's loaded up with a new round of financing and its stock price is hovering at recent lows, meaning investors may want to grab shares of this growing cancer diagnostics company.

In the wake of a broad market sell-off, investors clamor to find companies developing drugs to put an end to the coronavirus outbreak.

More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?

Amid ever-rising numbers of infected individuals, Qiagen believes it offers a quick solution to expedite testing for the virus.

If Corbus announces positive results this summer from two late-stage clinical trials, the current stock price could be a steal. But it's not for the faint of heart.

Zogenex's lead drug candidate may soon be approved to treat the same patients targeted by GW Pharmaceutials' Epidiolex.

This giant health insurer deserves a closer look.

Big drug developers reinvest revenues from cash-cow products to fuel the pipeline for the future.

Targeting a large and growing disease state, this drug developer's stock requires patience to reap future rewards.

Investing in this emerging cancer-focused biotech may just allow you to retire early.

Biohaven’s shares dropped after a failed clinical trial, and risk-tolerant investors are snapping them up.

This gene-editing biotech company rewarded those who invested in its cutting-edge technology.